Off-Label Promotion Still A Litigation Risk For Pharma Cos.
In the past several years, we have seen an evaluation of the First Amendment in the federal courts pertaining to the off-label promotion of the pharmaceutical and medical device products. Information...To view the full article, register now.
Already a subscriber? Click here to view full article